LIQUIDIA CORP (LQDA)
US53635D2027 - Common Stock
We assign a fundamental rating of 3 out of 10 to LQDA. LQDA was compared to 194 industry peers in the Pharmaceuticals industry. LQDA may be in some trouble as it scores bad on both profitability and health. LQDA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
LQDA had negative earnings in the past year.
In the past year LQDA has reported a negative cash flow from operations.
In the past 5 years LQDA always reported negative net income.
LQDA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LQDA has a worse Return On Assets (-47.24%) than 62.50% of its industry peers.
Looking at the Return On Equity, with a value of -108.10%, LQDA is doing worse than 60.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.24% | ||
| ROE | -108.1% | ||
| ROIC | N/A |
ROA(3y)-45%
ROA(5y)-52.84%
ROE(3y)-88.11%
ROE(5y)-96.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of LQDA (64.65%) is better than 69.79% of its industry peers.
In the last couple of years the Gross Margin of LQDA has declined.
The Profit Margin and Operating Margin are not available for LQDA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.65% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.31%
GM growth 5Y-2.67%
2. Health
2.1 Basic Checks
LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LQDA has more shares outstanding
Compared to 5 years ago, LQDA has more shares outstanding
The debt/assets ratio for LQDA is higher compared to a year ago.
2.2 Solvency
LQDA has an Altman-Z score of 0.67. This is a bad value and indicates that LQDA is not financially healthy and even has some risk of bankruptcy.
LQDA has a Altman-Z score (0.67) which is comparable to the rest of the industry.
LQDA has a Debt/Equity ratio of 0.90. This is a neutral value indicating LQDA is somewhat dependend on debt financing.
LQDA's Debt to Equity ratio of 0.90 is on the low side compared to the rest of the industry. LQDA is outperformed by 71.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.67 |
ROIC/WACCN/A
WACC8.98%
2.3 Liquidity
LQDA has a Current Ratio of 6.33. This indicates that LQDA is financially healthy and has no problem in meeting its short term obligations.
LQDA has a better Current ratio (6.33) than 71.88% of its industry peers.
A Quick Ratio of 6.33 indicates that LQDA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.33, LQDA is doing good in the industry, outperforming 72.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.33 | ||
| Quick Ratio | 6.33 |
3. Growth
3.1 Past
The earnings per share for LQDA have decreased strongly by -87.36% in the last year.
The Revenue for LQDA has decreased by -14.79% in the past year. This is quite bad
Measured over the past years, LQDA shows a very strong growth in Revenue. The Revenue has been growing by 45.20% on average per year.
EPS 1Y (TTM)-87.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y186.97%
Revenue growth 5Y45.2%
Sales Q2Q%20.94%
3.2 Future
The Earnings Per Share is expected to grow by 16.67% on average over the next years. This is quite good.
Based on estimates for the next years, LQDA will show a very strong growth in Revenue. The Revenue will grow by 81.68% on average per year.
EPS Next Y-34.7%
EPS Next 2Y-13.46%
EPS Next 3Y22.43%
EPS Next 5Y16.67%
Revenue Next Year-10.16%
Revenue Next 2Y66.81%
Revenue Next 3Y118.64%
Revenue Next 5Y81.68%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
LQDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LQDA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LQDA's earnings are expected to grow with 22.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.46%
EPS Next 3Y22.43%
5. Dividend
5.1 Amount
No dividends for LQDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIQUIDIA CORP
NASDAQ:LQDA (12/6/2024, 8:00:00 PM)
After market: 11.01 0 (0%)11.01
-0.47 (-4.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap931.89M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.24% | ||
| ROE | -108.1% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.65% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.33 | ||
| Quick Ratio | 6.33 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-87.36%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-34.7%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y186.97%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y